The client markets a high-cost capital technology used across multiple clinical indications. As clinical adoption grew internationally, reimbursement pathways were established in several new countries each year, driving a steady need for multiple reimbursement and HTA submissions annually, as well as evaluation of additional indications.
Local submissions were often supported by in-country consultants, but each submission required up-to-date systematic evidence. Re-running a full systematic literature review for every country application would have been costly, duplicative, and slow, creating risk of delays and inconsistent evidence packages across markets.
MTRC built a global, HTA-grade systematic literature review designed to meet the expectations of multiple reimbursement and HTA bodies and be efficiently updated over time. The deliverables included:
- Comprehensive, reproducible searches across major bibliographic databases (e.g., MEDLINE, EMBASE, Cochrane Library)
- Clear PICO-aligned inclusion/exclusion criteria and documented screening logic
- PRISMA flow and transparent study disposition
- Excluded studies list with justifications
- Structured evidence synthesis with outcomes-based reporting
- Standardized evidence tables capturing key data from all relevant publications
The SLR was initially developed for one indication, then expanded to cover four additional indications / treatment modes. For each indication, MTRC and the client agreed on an update frequency (every 6–12 months) to ensure an up-to-date version was always available for submissions, with ad hoc updates when market timelines required.
MTRC delivered multiple high-quality, submission-ready SLRs using a robust and transparent methodology.
MTRC also established a “live” update process that enabled the client to reuse a consistent evidence backbone across multiple markets. Completed scheduled updates every 6–12 months (and faster when required), reducing both cost and turnaround time compared with repeatedly commissioning new, country-specific reviews.
The “live” SLR program supported reimbursement and HTA submissions across multiple markets, including the Nordics, Ireland, Hungary, and the UAE.
Because the evidence base was methodologically rigorous and consistently updated, reimbursement and HTA bodies accepted it without material methodological objections, enabling the client to stay on schedule with submissions.
Over several years, the company avoided duplicative work by local consultants and achieved cumulative savings in the hundreds of thousands of euros, while improving consistency and submission readiness across indications and geographies.
Get in Touch
Contact us to discuss your needs and learn about our services